logo-loader

Outlook Therapeutics

Receive alerts
Market:
NASDAQ
Market Cap:
$37.55 m
Price
1.33 USD
Change
7.26%
52 weeks high
10.88
52 weeks low
0.85

In brief

Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a complex, technically challenging and commercially attractive monoclonal antibody, or mAb, for various ophthalmic indications.

Our goal is to launch ONS-5010 as the first, and only, approved bevacizumab in the United States, Europe, Japan and other markets for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).